Biotech News

MeiraGTx Reports Third Quarter 2026 Financial and Operational Results

MeiraGTx (MGTX)MeiraGTxEarnings

Submission of Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) expected in December 2026 Submission of full Biologics License Application (BLA) to the U.S.

Related news

MeiraGTx

Genetic Medicines Company MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing. Bota-Vec Botaretigene sparoparvovec is an AAV gene therapy for X-linked...

Recent company news

Stock data

Close
8.14 USD
Market cap
855.71M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States